Please ensure Javascript is enabled for purposes of website accessibility

Why iBio Stock Jumped Today

By Joe Tenebruso – Aug 28, 2020 at 1:58PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech struck a licensing deal for a potential coronavirus treatment.

What happened

Shares of iBio (IBIO -6.92%) climbed on Friday after the biologics manufacturer announced an exclusive global license agreement with Planet Biotechnology for the development of its experimental COVID-19 therapy. As of 1:25 p.m. EDT, iBio's stock was up 5% after rising as much as 18.5% earlier in the day.  

So what 

Planet Biotechnology's COVID-19 therapeutic candidate, labeled ACE2-Fc, is designed to have benefits similar to traditional neutralizing antibodies while reducing the likelihood of "viral escape" -- the ability of a virus to dodge a person's immune system. Planet Biotechnology said ACE2-Fc blocked SARS-CoV-2 -- the virus that causes COVID-19 -- from infecting Vero E6 cells during in vitro studies.

A stock chart that rises sharply then begins to fall.

iBio stock rose on news of a coronavirus therapy licensing deal. Image source: Getty Images.

iBio, meanwhile, said that its FastPharming, plant-based protein-production platform could help to accelerate the therapy's manufacture. "We believe the molecule may be effective against SARS-CoV-2 infection, and that it has the potential to be rapidly redesigned in the FastPharming System to address mutations in the current virus, if any, as well as future coronaviral diseases," iBio CEO Tom Isett said in a press release. 

Now what

Competition is intense among coronavirus therapy and vaccine makers. Billions of dollars in government funding have been awarded to healthcare giants, such as Pfizer, Johnson & Johnson, and AstraZeneca, and there are more than 170 coronavirus vaccine development projects currently under way around the world. This fierce competition makes smaller biotech companies like iBio relatively risky investments.

However, one area where iBio has an edge is its FastPharming manufacturing system, which uses plants to produce biological vaccines and medicines. It's a faster process that makes it easier for vaccine makers to quickly scale production. So, even if its own coronavirus vaccine candidates fail to produce the desired outcomes, investors can expect iBio to sign more manufacturing deals in the months ahead.

Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

iBio, Inc. Stock Quote
iBio, Inc.
IBIO
$0.34 (-6.92%) $0.03

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.